Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 299
Tipo Título / Nombre Autor(es) Año
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy Paiva B, Burgos L, , , Ahdadi A..., Bergua JM 2026
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients Olszewski AJ, Eradat HA, Avigdor A, Horowitz NA..., Bergua Burgues JM 2026
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia Bertoli S, Landberg N, Bérard E, Gondran C..., Bergua Burgues JM 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C..., Bergua Burgués JM 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, Arnán M, Martínez Sánchez P, Herrera-Puente P, Serrano-López J, Rubio V, Marchante-Cepillo I, Cervera-Calvo M, Novo García A, Fernández Martín R, Gil Cortés C, Rodríguez-Medina C, Noriega-Concepción V, Alfonso-Piérola A, Loredo C, Antuña-Casal M, Boluda B, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Sánchez-García J, Bilbao C, Gómez-Casares MT, Martínez Cuadrón D, Montesinos P 2026
Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study Barragán E, Gil JV, Ayala R, Chillón C..., Bergua J 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, López-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH 2026
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study Gil JV, Sargas C, Ayala R, Gutierrez NC..., Bergua Burgues JM 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group Colmenares R, Barragán E, Rodríguez-Veiga R, Torres-Miñana L..., Bergua J 2026
Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Torrent A, Morgades M..., Bergua Burgues JM 2026